跳至主要内容
临床试验/CTRI/2017/09/009774
CTRI/2017/09/009774招募中2/3 期

Efficacy and Safety of ALERT Capsule in the Managment of Generalized Anxiety Disorder-An Open Label Clinical Study

Vasu Research Centre VRC A Division of VASU Health Care Pvt Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2016年4月4日最近更新:

试验速览

阶段
2/3 期
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
Primary outcomes will be effect of drug on subjective and objective parameters

研究概览

简要总结

Generalized anxiety disorder (GAD) is characterized by excessive,uncontrolled and often irrational worry, that is, apprehensive expectationabout events or activities. In India, around 6-10% population is suffering fromGAD. Anxiolytic drugs are extremely tempting, and prescribed to millions of individualssuffering from anxiety and stress. But some of them (like Benzodiazepines,Buspirone) are known to produce side effects like hypotension, nausea, memoryloss, sexual dysfunction, headache etc. Thus, it needs tosearch for safe and effective solution. Thepresent study is to be initiated for evaluating clinical efficacy and safety ofAlert Capsule in the management of Generalized Anxiety Disorder (GAD). Diseasespecific inclusion and exclusion criteria have been selected and shallbe employed for the enrolment of patients. For the assessment of efficacyappropriate subjective parameters like Generalized Anxiety Disorder 7 (GAD-7)scale, Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale(HAM-D), WHO Quality of life BREF, Pittsburg sleep quality index, Clinicalglobal Impression will be used. On another hand, bio-chemical parameter likeserum cortisol level will be analysed as anxiety marker other investigationslike liver Function test, Renal Function test, Complete blood profile like Hb,ESR, RBC, PCV, MCV, MCH, MCHC, WBC, WBC Differential, total platelet count, MPVand blood clotting time will be evaluated. Urine & Stool routineexamination will also be carried out.   Total study period in a patient will be of 60days. Treatment with test drug will be provided for 1 month and followed by 1month period of placebo interventional observation period. Follow-up visit isto be scheduled at every 2 weeks of interval with 4 follow up. All thelaboratory investigations will be carried out at base line and 30th day.However evaluation with all the clinical assessment scales will be carried outat all the visits.  Appropriate statisticstools shall be applied to find out statistical significance of undergoingtherapy.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Day(s) 至 60.00 Day(s)(—)
性别
All

入选标准

  • (1)Patients (Male & Female) between the age group of 18 and 60 years and willing to give consent to participate in the study.
  • (2)Patients having Generalized Anxiety Disorder 7 (GAD-7) score ≥ 10 (3)Patients having Hamilton Anxiety Rating Score (HAM-A) ≥ 11 (4)Patients suffering from psycho- physiological insomnia especially due to anxiety.

排除标准

  • (1)Patients below 18 years and above 60 years (2)Patients with Hamilton Depression Rating Scale score >13 (3)Patients suffering from any serious liver, kidney and cardiac diseases.
  • (4)Patients having history of any genetic disorders (5)Patients on hypnotic medicine or other drugs which known to cause drowsiness.
  • (6)Lactating & pregnant women (7)Patients on any Psychotropic or Nuerotrophic drugs 4 weeks prior to the study.

结局指标

主要结局

Primary outcomes will be effect of drug on subjective and objective parameters

时间窗: baseline, 15th, 30th, 45th & 60th day

次要结局

  • Assessment of drug safety and patient’s compliance(base line, 15th day, 30th day, 45th day, 60th day)

研究者

发起方
Vasu Research Centre VRC A Division of VASU Health Care Pvt Ltd
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验